Related Experiment Videos
Immunotherapy for metastatic renal cell carcinoma
1Department of Urology, Medical School, Dresden, Germany.
The Urologic Clinics of North America
|May 1, 1993
Summary
Previous immunotherapies for renal cell carcinoma showed low response rates. Cytokine therapies, including interferon-alpha and IL-2, offer limited remission and survival benefits, warranting further clinical trials.
Area of Science:
- Oncology
- Immunology
Background:
- Autologous tumor cell, tumor cell vaccine, and immune RNA immunotherapies for renal cell carcinoma (RCC) showed limited efficacy.
- Cytokine therapies, including interferons (IFN), interleukin-2 (IL-2), and tumor necrosis factor (TNF), have been widely investigated for advanced RCC.
Purpose of the Study:
- To evaluate the efficacy and safety of cytokine-based immunotherapies for advanced renal cell carcinoma.
- To assess the potential of combined interferon-alpha and IL-2 therapy in RCC treatment.
Main Methods:
- Review of previous studies on immunotherapy and cytokine therapy for renal cell carcinoma.
- Analysis of objective remission rates and survival data from patients treated with cytokines.
Main Results:
- Immunotherapies demonstrated low response rates in renal cell carcinoma treatment.
- Cytokine therapies, including IFN and IL-2, rarely achieved objective remission rates exceeding 20% and did not significantly improve survival.
- Subcutaneous administration of IFN-alpha and IL-2 showed comparable results to other modalities with reduced morbidity.
Conclusions:
- Current cytokine therapies for advanced renal cell carcinoma offer limited clinical benefit.
- Lack of established treatment schedules and defined patient populations for cytokine therapy necessitates its use within prospective clinical trials.